Лекарственное лечение метастатического рака молочной железы
Аннотация
В статье представлены основные принципы лекарственной терапии метастатического рака молочной железы, рассмотрены варианты лечения этого заболевания. Проанализированы и подробно описаны режимы гормоно- и химиотерапии, дана оценка эффективности препаратов, применяемых в этих режимах, и различных их комбинаций.
Список литературы
1. Saad E., Katz A., Machado K., Buyse M. Post-progression survival (PPS) and overall survival (OS) according to treatment type in contemporary phase III trials in advanced breast cancer (ABC). SABCS 2009; abstr 5116. 2. Dawood S., Broglio K., Gonzalez-Angulo A.M. et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2008;26:4891–8.
2. DeVita V., Lawrence T., Rosenberg S. et al. DeVita, Hellman, and Rosenberg’s cancer: principles and practice of oncology. Philadelphia: J.B. Lippincott, 2008; p. 1634.
3. Perou C.M. Molecular stratification of triple-negative breast cancer. Oncologist 2011;16(Suppl 1):61–70.
4. Mauri D., Pavlidis N., Polysos N.P., Ioannidis J.P.I. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006;98(18):1285–91.
5. Bonneterre J. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000;18:3748–57.
6. Mouridsen H., Gershanovich M., Sun Y. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19(10):2596–606.
7. Mouridsen H., Gershanovich M., Sun Y. et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21(16):2101–9.
8. Robertson J.F.R., Lindemann J.P.O., Llombart-Cussac A. et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the «FIRST» study. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; Dec 8–12, 2010; San Antonio, TX; abstr 1–3.
9. Osborne C.K., Pippen J., Jones S.E. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American Trial. J Clin Oncol 2002;20 (16):3386–95.
10. Howell A., Robertson J.F., Quaresma Albano J. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Clin Oncol 2002; 20(16):3396–403.
11. Chia S., Gradishar W., Mauriac L. et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26(10):1664–70.
12. Steele N., Zekri J., Coleman R. et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non- steroidal aromatase inhibitor failure. Breast 2006;15:430–6.
13. Carlini P., Michelotti A., Ferretti G. et al. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest 2007;25:102–5.
14. Lonning P.E., Bajetta E., Murray R. et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234–44.
15. Fossati R., Confalonieri C., Torri V. et al. Cytotoxic and hormonal treatment of metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439–60.
16. O’Shaughnessy J., Miles D., Vukelja S. et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;15:2812–23.
17. Albain K.S., Nag S., Calderillo-Ruiz G. et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc. ASCO 2004;23:5; abstr 510.
18. Martin M., Ruiz A., Munoz M. et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final
19. results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8(3):219–25.
20. Falkson G., Gelman R.S., Pandya K.J. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998;16:1669–76.
21. Gennari A. et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29:2144–9.
22. Beslija S., Bonneterre J., Burstein H.J. et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20:1771–85.
23. Stadtmauer E.A., O'Neill A., Goldstein L.J. et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342:1069–76.
24. Kennedy R.D., Quinn J.E., Mullan P.B. et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659–68.
25. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568–581.
26. Von Hoff D.D. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–7.
27. Praga C., Trave F., Petroccione A. et al. Anthracycline- induced cardiotoxicity and its relevance in cancer treatment. Clinical measurement in drug evaluation. London: Wolfe Publishing, 1991; p. 132–42.
28. Trudeau M. First-line treatment of metastatic breast cancer. Anti-cancer Drugs 1996;7(Suppl 2):9–12.
29. Stockler M.R., Sourjina T., Grimison P. et al. A randomized trial of capecitabine (C), given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 2007;25(Suppl 18):39; abstr 1031.
30. Zielinski C., Gralow J., Martin M. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010;21(11):2145–52.
31. O’Shaughnessy J.A., Blum J., Moiseyenko V. et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/ metastatic breast cancer. Ann Oncol 2001;12(9):1247–54.
32. Piccart-Gebhart M.J., Burzykowski T., Buyse M. et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008 ;26:1980–6.
33. Jones S.E., Overmoyer B. et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23(24):5542–51.
34. Seidman A., Berry D., Cirrincione C. et al. CALGB 9840: phase III study of weekly (w) paclitaxel via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER-2 positive metastatic breast cancer and randomized for T in HER-2 normal MBC. Proc ASCO 2004 (J Clin Oncol 2004);22:6; abstr 512.
35. Cortazar P., Johnson J.R., Justice R., Pazdur R. Metastatic breast cancer (MBC): FDA approval overview. Proc ASCO 2008 (J Clin Oncol 2008);26(Suppl 15); abstr 1013.
36. Mansutti M., Cavazzini G., Lorusso V. et al. Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC). Proc ASCO 2008 (J Clin Oncol 2008);26(Suppl 15):1034.
37. Peacock N.W., Infante J.R., Yardley D.A. et al. Phase II trial of weekly docetaxel, vinorelbine and trastuzumab in the first-line treatment of patients (pts) with HER-2-positive metastatic breast cancer (MBC). Proc ASCO 2008 (J Clin Oncol 2008); 26(Suppl 49); abstr 1032.
38. Kash J., Barlow W.E., Albain K.S. et al. Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER-2-positive stage IV breast cancer. Proc ASCO 2008 (J Clin Oncol 2008);26(Suppl 49); abstr 1033.
39. Seidman A., Hudis C., Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215–21.
40. Keefe D.L. Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592–600.
41. Robert N., Leyland-Jones B., Asmar L. et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786–92.
42. Pegram M., Forbes J., Pienkowski T. et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). Proc ASCO 2007; 1(25):18; abstr LBA100.
43. Wardley A., Anton-Torres A., Pivot X. et al. Trastuzumab plus docetaxel with or without capecitabine in patients with HER2- positive advanced/metastatic breast cancer: first efficacy results from the phase II MO16419 (CHAT) study. Breast Cancer Res Treat 2006;100(Suppl 1):101.
44. Kaufman B., Mackey J.R., Clemens M.R. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27(33):5529–37.
45. Bartsch R., Wenzel K., Altorjai G. et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:3853–8.
46. Von Minckwitz G., Vogel P., Schmidt M. et al. Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer: the TBP study (GBG 26/BIG 3-05). Breast Cancer Res Treat 2007;106:185–4056.
47. Von Minckwitz G., Zielinski C., Maarteense E. et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05). Proc ASCO 2008; abstr 1025.
48. Von Minckwitz G., du Bois A., Schmidt M. et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27:1999–2006.
49. Extra J.M., Antoine E.C., Vincent- Salomon A. et al. Favourable effect of trastuzumab (Herceptin) treatment in metastatic breast cancer patients: results from the French Hermine cohort study. Breast Cancer Res Treat 2006;100(Suppl 1):102.
50. O’Shaughnessy J., Blackwell L., Burstein H. et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc ASCO 2008;abstr 1015.
51. Geyer C.E. et al.; EGF100151. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733–43.
52. Wagner L., Wang M., Miller K. et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat 2006;100(Suppl 1):239 (abstr).
53. Miles D., Chan A., Romieu G. et al. Randomized, double-blind, placebo- controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients AVADO. J Clin Oncol 2008;26 (Suppl): abstr LBA1011.
54. Miller K.D., Chap L.I., Holmes F.A. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792–9.
55. Miller K., Wang M., Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666–76.
56. Diel I.J. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 2007; 15:1243–9.
57. Stopeck A.T., Lipton A., Body J.J. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28(35):5132–9.
Для цитирования:
Артамонова Е.В. Лекарственное лечение метастатического рака молочной железы. Опухоли женской репродуктивной системы. 2011;(4):46-53. https://doi.org/10.17650/1994-4098-2011-0-4-46-53
For citation:
Artamonova E.V. Drug treatment for metastatic breast cancer. Tumors of female reproductive system. 2011;(4):46-53. (In Russ.) https://doi.org/10.17650/1994-4098-2011-0-4-46-53
Просмотров: 220
Послать статью по эл. почте 